Treatment Interruption of Natalizumab
Public ClinicalTrials.gov record NCT01071083. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Treatment Interruption of Natalizumab
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, rater blinded trial in patients who interrupt treatment with natalizumab with or without being treated with other immunomodulatory drugs, or continue treatment with natalizumab. The main purpose of this study is to find out the following, when participants stop taking natalizumab for 24 weeks: * when MS symptoms return, and * if other drugs for MS may help control MS symptoms during the natalizumab-interruption period. This study will also explore how quickly the effects of natalizumab return after resuming natalizumab dosing.
Study identification
- NCT ID
- NCT01071083
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 175 participants
Conditions and interventions
Conditions
Interventions
- natalizumab Drug
- interferon beta 1-a Drug
- methylprednisolone Drug
- IV placebo Other
- glatiramer acetate Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2010 (Type not available)
- Primary completion
- Nov 2011 (Actual)
- Completion
- Nov 2011 (Actual)
- Last update posted
- Sep 19, 2013
2010 – 2011
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Cullman | Alabama | 35058 | — |
| Research Site | San Francisco | California | 94117 | — |
| Research Site | Fort Collins | Colorado | — | — |
| Research Site | Pompano Beach | Florida | 33060 | — |
| Research Site | Atlanta | Georgia | 30309 | — |
| Research Site | Atlanta | Georgia | 30327 | — |
| Research Site | Chicago | Illinois | 60612 | — |
| Research Site | Lake Barrington | Illinois | 60010 | — |
| Research Site | Des Moines | Iowa | 50314 | — |
| Research Site | Boston | Massachusetts | 2135 | — |
| Research Site | Boston | Massachusetts | 2215 | — |
| Research Site | Buffalo | New York | 14203 | — |
| Research Site | Latham | New York | 12110 | — |
| Research Site | Patchogue | New York | 11772 | — |
| Research Site | Charlotte | North Carolina | 28207 | — |
| Research Site | Raleigh | North Carolina | 27607 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Uniontown | Ohio | — | — |
| Research Site | Salt Lake City | Utah | 84103 | — |
| Research Site | Seattle | Washington | 98111 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01071083, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 19, 2013 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01071083 live on ClinicalTrials.gov.